Clinical trials: Sorafenib
Carcinoma, Renal Cell
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
The purpose of the study is to: Find out if BAY 43-9006 prevents the growth of tumors For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or…
- Trial name
- NCT00079612
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 501 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
This is a study to investigate the potential clinical benefit of refametinib when given in combination with sorafenib as first line treatment in patients with unresectable or metastatic HCC carrying a RAS mutation.
- Trial name
- NCT01915602
- Testing
- Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
- Where
- 79 sites in United States, Austria and 19 more
- Volunteers
- 14 people
- Sponsor
- Bayer
Carcinoma, Renal Cell, Carcinoma, Renal Cell (Advanced)
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis.
- Trial name
- NCT00895674
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 18 sites in Argentina, Austria and 16 more
- Volunteers
- 2,840 people
- Sponsor
- Bayer
Hepatocellular Carcinoma, Liver Cancer
First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
MNA-3521-011 study is a multi-centre, open-label, first-in-human, phase 1a/b clinical study dose/dose frequency escalation followed by a cohort expansion part.
- Trial name
- OUTREACH (NCT02716012)
- Testing
- MTL-CEBPA, Sorafenib 200mg
- Where
- 11 sites in Singapore, Taiwan and 1 more
- Volunteers
- 75 people
- Sponsor
- Mina Alpha Limited
Hepatocellular Carcinoma
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 open-label, single-arm, non-randomized study in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with sorafenib using a Simon's 2-stage design.
- Trial name
- NCT01752933
- Testing
- SGI-110
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Hepatocellular Carcinoma
Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made.
- Trial name
- STELLA (NCT01539681)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Italy
- Volunteers
- 234 people
- Sponsor
- Bayer
Thyroid Neoplasms
An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any…
- Trial name
- RIFTOS MKI (NCT02303444)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Other Multikinase inhibitors
- Where
- 34 sites in United States, Algeria and 17 more
- Volunteers
- 667 people
- Sponsor
- Bayer
Neoplasm, Metastasis
Extension Program for Bay 43-9006
The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the…
- Trial name
- NCT00657254
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 9 people
- Sponsor
- Bayer
Carcinoma, Renal Cell
Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer
The objective of this Non-Interventional study is to evaluate the effectiveness \& safety of Nexavar in advanced Renal Cell Carcinoma (RCC) patients under daily-life treatment conditions based on age of the patient (older (age…
- Trial name
- POWER-NEXT (NCT01353794)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Sponsor
- Bayer
Kidney Cancer
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are: To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in…
- Trial name
- NCT00498966
- Testing
- Perifosine
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- AEterna Zentaris
Carcinoma, Hepatocellular
A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
This open-label study will assess the safety, efficacy and pharmacokinetics of RO5323441 in combination with sorafenib in patients with advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
- Trial name
- NCT01308723
- Testing
- RO5323441, sorafenib
- Where
- 2 sites in Singapore
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Renal Cell
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
This treatment protocol allows doctors to treat advanced kidney cancer with an investigational drug called sorafenib, BAY43-9006, which is being studied in clinical trials for kidney cancer and other kinds of cancer.
- Trial name
- NCT00111020
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 320 sites in United States, Canada
- Volunteers
- 2,567 people
- Sponsor
- Bayer
HCC
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine if VT-122 provides a clinical benefit when added to Sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT01265576
- Testing
- Sorafenib, VT-122 (propranolol plus etodolac)
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- Vicus Therapeutics
Carcinoma, Renal Cell
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who…
- Trial name
- NCT00073307
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 121 sites in United States, Argentina and 17 more
- Volunteers
- 903 people
- Sponsor
- Bayer
Renal Cell Carcinoma
Tumor Registry of Advanced Renal Cell Carcinoma
The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.
- Trial name
- RCC-Registry (NCT00610012)
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- iOMEDICO AG
Carcinoma, Renal Cell
Research Study for Patients With Metastatic Renal Cell Carcinoma
This study has been designed to study patients diagnosed with advanced renal cell cancer with the primary tumor in place.
- Trial name
- NCT00110344
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Melanoma
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
The purpose of this study is to see whether a new type of anti-cancer drug, known as BAY 43-9006, can be given safely and with good effect in combination with dacarbazine (DTIC).
- Trial name
- NCT00492297
- Testing
- Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)
- Where
- 12 sites in France, United Kingdom
- Volunteers
- 83 people
- Sponsor
- Bayer
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured adult patients.
- Trial name
- NCT01381601
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular…
- Trial name
- NCT00687596
- Testing
- TAC-101
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Gastric Cancer
Sorafenib Gastric Cancer Asian Phase I Study
This study is to investigate safety, pharmacokinetics and preliminary efficacy profile of sorafenib in combination with S-1 plus cisplatin in Asian patients with unresectable / recurrent gastric cancer.
- Trial name
- NCT00663741
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 3 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Bayer